1 de 10 sur environ 218 communiqués.
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Biomanufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering. This research report presents an in-depth...
Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type, by Workflow, by Application, by End User - Global Forecast to 2025 -...
Research and Markets
Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. In-depth...
Research and Markets
Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market by Product, by Material, by Application - Global Opportunity Analysis and Industry Forecast, 2020 - 2030" report has been...
Research and Markets
Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "3D Cell Culture Market by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to...
Research and Markets
Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report...
Sana Biotechnology, Inc
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its...
Research and Markets
Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Technologies Market Report - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The Global Cell Therapy...
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the...
Bone Therapeutics SA
INFORMATION REGLEMENTÉE Le développement des programmes cliniques et plus particulièrement de l’essai de Phase III évaluant JTA-004 et de l’essai de Phase IIb évaluant ALLOB, se poursuit...
1 de 10 sur environ 218 communiqués.
